Comprehensive analysis of Kotak Healthcare Fund - Direct (IDCW) (44439) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Kotak Mahindra Asset Management Company Ltd
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefiting directly or indirectly Pharma, Healthcare, and allied sectors. However, there is no assurance that the objective of the scheme will be achieved.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Moderate Returns
High Risk
Low Expense Ratio
Equity Focused
New Team
Average Quality
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Outperformance vs benchmark
Historical performance consistency
Market exposure level
Recent performance momentum
Fund management costs
Risk-adjusted returns
Fund manager experience
Assets under management
This fund has outperformed its benchmark by 1.81% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | Pharmaceuticals | 14.07% |
| Max Healthcare Institute Ltd | Healthcare | 7.83% |
| J B Chemicals & Pharmaceuticals Ltd | Pharmaceuticals | 5.87% |
| TREPS | Debt Others | 5.85% |
| Divis Laboratories Ltd | Pharmaceuticals | 5.44% |
| Cipla Ltd | Pharmaceuticals | 4.81% |
| Apollo Hospitals Enterprise Ltd | Healthcare | 4.09% |
| Jubilant Pharmova Ltd | Pharmaceuticals | 3.44% |
| Fortis Healthcare Ltd | Healthcare | 3.18% |
| Gland Pharma Ltd | Pharmaceuticals | 2.98% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 3M | 6M | 1Y |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1540.61 | 4.17% | 20.90% | -2.29% |
| Aditya Birla SL MNC Fund - (G) | ₹1383.22 | 3.98% | 20.48% | -2.95% |
| Nippon India Banking&Financial Services-Dir(G) | ₹662.94 | -2.23% | 13.57% | 4.61% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹662.94 | -2.23% | 13.57% | 4.61% |
| Nippon India Banking&Financial Services (G) | ₹606.00 | -2.44% | 13.09% | 3.74% |
| Nippon India Banking&Financial Services (Bonus) | ₹606.00 | -2.44% | 13.09% | 3.74% |
| Nippon India Pharma Fund - Direct (G) | ₹574.98 | 2.59% | 13.30% | 0.45% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹574.98 | 2.59% | 13.30% | 0.45% |
| Franklin India Technology Fund - Direct (G) | ₹565.29 | 3.31% | 7.85% | -5.66% |
| ICICI Pru FMCG Fund - Direct (G) | ₹542.41 | 3.11% | 13.18% | -7.36% |
A seasoned investment professional with over 2 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.